Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
about
Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sexA mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineBiomarkers and human hepatocytes.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Transporter assays as useful in vitro tools in drug discovery and development.The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors.Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative ProteomicsPhysiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective.Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.Role of enterohepatic recirculation in drug disposition: cooperation and complications.A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”
P2860
Q30776360-554EB36A-4E1B-49A5-816A-D3DF3D9DA2B0Q36972804-31C686DB-C7B2-4D64-9154-3C61FB205812Q37422685-BBDD8B03-E49C-460A-AB18-B635A503584AQ37470663-6AF03082-D51A-49B4-B0B4-30E4A01EA217Q38187449-38782F09-2423-4609-92E7-1F5C216B9F2CQ38214334-A460B527-A533-48E2-99FA-72B0FE9994C5Q38233298-F6186149-D94B-4B6E-A669-43D2DEF5B587Q38302225-5CACAE03-4244-4978-8B49-24648209F75DQ38619057-59AB0641-B987-484E-B5C0-9BAD17A0C3DFQ38750759-7BA8CB04-8705-42FC-A01B-40EC564385C9Q38829596-F9AF1B27-395D-4F0C-8827-B73FD1AF96A1Q38836056-818B6A0E-C754-4489-BED2-1350EDEC8C20Q38844656-6E2E7778-61F7-473D-B3F1-462F63F63344Q38855314-5825D827-915B-4C46-ADFB-4D84E7D00D89Q38933872-E48AAE3D-5D65-4618-AB6D-7F2032006339Q39101424-913855FD-1387-41E7-A3FF-AD7501DD6F8FQ39178447-4137B5E1-1D20-4260-8A1B-7062868D74A4Q39264028-A6F5686E-818C-4BF9-BED5-63B187BB8F12Q39418438-8C82F8E6-8C0C-4DDF-876A-0BDA2BCD0555Q40192653-C531E0F4-9563-4938-A29C-5C14E4E1AD44Q41150870-B2C6C123-C11D-4735-BAF5-84044AB74047Q41737190-FD1E944E-CADA-47EA-B4E9-DE5F71127B07Q45243894-155D4E6A-1A56-40BF-8855-03A9D883956AQ46578287-D960D846-4975-4991-8E59-E78B33FA57DEQ46942949-3A7E5531-1E8C-45C9-96CE-AB973EF9A85DQ47267937-8F807FBA-0096-4B82-B976-1D19AD22AD56Q47592224-338CE276-AE92-45F1-AE2F-7CAA2AA4BAF1Q48142540-39BA5FEA-43AF-4D32-80E2-CA82AEDB2DF4Q50050263-A377F1A0-43D0-45FB-8688-495D3AFEB299Q51485773-2B0C4878-0585-4E8B-AECC-53BE1412A6DDQ54053216-72CF81E5-3949-4563-98B2-E08CD6638593Q57684330-26D7458E-1DB3-4E21-B0ED-EF25DBB5F7E5
P2860
Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mechanistic modeling to predic ...... g interactions of repaglinide.
@en
Mechanistic modeling to predic ...... g interactions of repaglinide.
@nl
type
label
Mechanistic modeling to predic ...... g interactions of repaglinide.
@en
Mechanistic modeling to predic ...... g interactions of repaglinide.
@nl
prefLabel
Mechanistic modeling to predic ...... g interactions of repaglinide.
@en
Mechanistic modeling to predic ...... g interactions of repaglinide.
@nl
P2093
P2860
P1476
Mechanistic modeling to predic ...... g interactions of repaglinide.
@en
P2093
Ayman F El-Kattan
Emi Kimoto
Manthena V S Varma
Theunis C Goosen
Vikas Kumar
Yurong Lai
P2860
P304
P356
10.1007/S11095-012-0956-5
P577
2013-01-10T00:00:00Z